Australian shares closed the week higher, tracking Asian markets, despite Wall Street's concerns about high interest rates.
The S&P/ASX 200 Index rose 0.6% or 49.3 points to close at 8,250.5.
Anticipated fewer rate cuts from the US Federal Reserves, coupled with potential inflationary policies from President-elect Trump hit shares while sending bond yields higher and making the dollar stronger, Reuters reported.
In company news, the Australian Securities Exchange (ASX:ASX) is looking to clamp down on listed companies allegedly providing misleading or evasive information in their market disclosures, according to a report by The Australian.
Imugene (ASX:IMU) dosed the first Australian patient for its phase 1b clinical trial of its CAR T-cell therapy azer-cel at the Royal Prince Alfred Hospital in Sydney.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。